Reacciones de hipersensibilidad a quimioterapéuticos y biológicos

Palabras clave: hipersensibilidad a las drogas, alergia, agentes antineoplásicos, terapia biológica, desensibilización.

Resumen

Las reacciones a medicamentos han aumentado con el tiempo, estas implican ahora una carga importante de enfermedad, principalmente en los servicios de hospitalización. Los agentes quimioterapéuticos y biológicos son fármacos utilizados con frecuencia en enfermedades reumatológicas y neoplasias de diferente orden. Las reacciones de hipersensibilidad a quimioterapéuticos y monoclonales impactan en la calidad de vida, el pronóstico y la mortalidad de los pacientes con enfermedades autoinmunes y cáncer, es por eso que deben ser reconocidas y manejadas por un equipo de trabajo multidisciplinar. La desensibilización es una herramienta terapéutica que ofrece grandes beneficios a los pacientes con reacciones de hipersensibilidad, permitiéndoles la utilización de medicamentos de primera línea de manera segura y costoefectiva, con un impacto importante en la morbilidad y mortalidad de estos pacientes. El objetivo de este artículo fue revisar la información y evidencia más reciente sobre las reacciones de hipersensibilidad a quimioterapéuticos y biológicos, y los datos sobre las opciones de desensibilización con estos medicamentos y su desenlace.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Diana María Martínez-Castillo, Universidad de Antioquia

Médica, Residente de Alergología Clínica, Universidad de Antioquia. Medellín, Colombia.
https://orcid.org/0000-0002-1692-7738.

Juan Camilo Ardila-Herrera, Universidad de Antioquia

Médico, Residente de Alergología Clínica, Universidad de Antioquia. Medellín, Colombia.
https://orcid.org/0000-0002-4520-7975.

Ana María Calle-Álvarez, Hospital San Vicente Fundación

Médica, Especialista en Alergología Clínica. Docente, Hospital San Vicente Fundación. Medellín, Colombia.

Carlos Fernando Chinchilla-Mejía, IPS Universitaria, Universidad de Antioquia

Médico, Especialista en Pediatría, Especialista en Alergología Clínica, . Profesor, Universidad de Antioquia. Medellín, Colombia. https://orcid.org/0000-0003-0456-5087.

Referencias bibliográficas

Jiménez ÓE, Navarro-Pemán C, González-Rubio F, Lanuza-Giménez FJ, Montesa-Lou C. Análisis de la incidencia y de las características clínicas de las reacciones adversas a medicamentos de uso humano en el medio hospitalario. Rev Esp Salud Publica 2017;91:1-17.

Organización Mundial de la Salud. Vigilancia de la seguridad de los medicamentos. Sistema de notificación para el público en general. Ginebra, Suiza: OMS; 2012. Acceso 15 de julio de 2021. Disponible en https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHO-UMC_ReportingGeneralPublic-ESP-GRA3Final.pdf.

Bush T. Adverse drug reactions in hospitalized patients. JAMA 1998;280:1742-1744.

Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005;5:309-316. https://doi.org/10.1097/01.all.0000173785.81024.33.

Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011;71:684-700. https://doi.org/10.1111/j.1365-2125.2010.03774.x.

Jares EJ, Sánchez-Borges M, Cardona-Villa R, Ensina LF, Arias-Cruz A, Gómez M, et al. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol 2014;113:282-289. https://doi.org/10.1016/j.anai.2014.06.019.

Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003;90:342-347. https://doi.org/10.1016/s1081-1206(10)61804-2.

Giavina-Bianchi P, Jares E, Aun MV, Thong B. Drug hypersensitivity reactions in the Americas: Similarities and differences. Ann Allergy Asthma Immunol 2019;122:447-448. https://doi.org/10.1016/j.anai.2019.02.007.

Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J 2020;29:32-61. https://doi.org/10.1007/s15007-020-2550-1.

Hong D, Sloane DE. Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases. Ann Allergy Asthma Immunol 2019;123:35-41. https://doi.org/10.1016/j.anai.2019.04.015.

Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin North Am 2017;37:397-412. https://doi.org/10.1016/j.iac.2017.01.012.

Sala-Cunill A, Luengo O, Cardona V. Biologics and anaphylaxis. Curr Opin Allergy Clin Immunol 2019;19:439-446. https://doi.org/10.1097/aci.0000000000000550.

Quercia O, Emiliani F, Foschi FG, Stefanini GF. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol 2011;106:547-548. https://doi.org/10.1016/j.anai.2011.03.014.

Soyer O, Demir S, Bilginer Y, Batu ED, Sonmez HE, Arıcı ZS, et al. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases. Pediatr Allergy Immunol 2019;30:833-840. https://doi.org/10.1111/pai.13114.

Akarsu A, Soyer O, Sekerel BE. Hypersensitivity reactions to biologicals: From bench to bedside. Curr Treat Options Allergy 2020;7:71-83. https://doi.org/10.1007/s40521-020-00242-2.

Sanchez-Piedra C, Hernández-Miguel MV, Manero J, Roselló R, Sánchez-Costa JT, Rodríguez-Lozano C, et al. Objetivos y metodología de la fase III de BIOBADASER. Reumatol Clin 2019;15:229-236. https://doi.org/10.1016/j.reuma.2017.08.001.

Vultaggio A, Castells MC. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin North Am 2014;34:615-632. https://doi.org/10.1016/j.iac.2014.04.008.

Vultaggio A, Matucci A, Parronchi P, Rossi O, Palandri F, Romagnani S, et al. Safety and tolerability of infliximab therapy: Suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol 2008;21:367-374. https://doi.org/10.1177/039463200802100214.

Pichler WJ. Adverse side-effects to biological agents. Allergy 2006;61:912-920. https://doi.org/10.1111/j.1398-9995.2006.01058.x.

Chitnavis M, Stein DJ, Commins S, Schuyler AJ, Behm B. First-dose anaphylaxis to infliximab: a case of mammalian meat allergy. J Allergy Clin Immunol Pract 2017;5:1425-1426. https://doi.org/10.1016/j.jaip.2017.04.044.

Arnold DF, Misbah SA. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358:2735-2736. https://doi.org/10.1056/NEJMc080834.

Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007;28:313-319. https://doi.org/10.2500/aap.2007.28.3003.

Perino E, Freymond N, Devouassoux G, Nicolas JF, Berard F. Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate. Ann Allergy Asthma Immunol 2018;120:664-666. https://doi.org/10.1016/j.anai.2018.02.018.

Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol 2014;24:212-225.

del Carmen-Sancho M, Breslow R, Sloane D, Castells M. Desensitization for hypersensitivity reactions to medications. Chem Immunol Allergy 2012;97:217-233. https://doi.org/10.1159/000335637.

Khan DA. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. Ann Allergy Asthma Immunol 2016;117:115-120. https://doi.org/10.1016/j.anai.2016.05.013.

Wing M. Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxicol 2008;5:11-15. https://doi.org/10.1080/15476910801897433.

Yildizhan E, Kaynar L. Cytokine release syndrome. J Oncol Sci 2018;4:134-141. https://doi.org/https://doi.org/10.1016/j.jons.2018.09.002.

Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol 2017;140:335-348. https://doi.org/10.1016/j.jaci.2017.06.003.

Isabwe GAC, Garcia-Neuer M, de Las Vecillas-Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. J Allergy Clin Immunol 2018;142:159-170. https://doi.org/10.1016/j.jaci.2018.02.018.

Bavbek S, Ataman Ş, Akıncı A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract 2015;3:629-632. https://doi.org/10.1016/j.jaip.2015.01.009.

O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014;20:1-6. https://doi.org/10.1097/01.MIB.0000436951.80898.6d.

Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002;13:1948-1950. https://doi.org/10.1093/annonc/mdf350.

Urosevic-Maiwald M, Harr T, French LE, Dummer R. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer. Int J Dermatol 2012;51:864-867. https://doi.org/10.1111/j.1365-4632.2011.05356.x.

Karmacharya P, Poudel DR, Pathak R, Donato AA, Ghimire S, Giri S, et al. Rituximab-induced serum sickness: A systematic review. Semin Arthritis Rheum 2015;45:334-340. https://doi.org/10.1016/j.semarthrit.2015.06.014.

Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011;7:55-63. https://doi.org/10.1586/eci.10.90.

Vitte J, Amadei L, Gouitaa M, Mezouar S, Zieleskiewicz L, Albanese J, et al. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study. Allergy 2019;74:1157-1165. https://doi.org/10.1111/all.13752.

Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004;114:371-376. https://doi.org/10.1016/j.jaci.2004.04.029.

Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702-712. https://doi.org/10.1111/all.12142.

Hong DI, Dioun AF. Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children. J Allergy Clin Immunol Pract 2014;2:13-19. https://doi.org/10.1016/j.jaip.2013.11.007.

Bonamichi-Santos R, Castells M. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: Reactions to taxanes and monoclonal antibodies. Clin Rev Allergy Immunol 2018;54:375-385. https://doi.org/10.1007/s12016-016-8556-5.

Castells MC. Anaphylaxis to chemotherapy and monoclonal antibodies. Immunol Allergy Clin North Am 2015;35:335-348. https://doi.org/10.1016/j.iac.2015.01.011.

Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-72. https://doi.org/10.1038/nrc1529.

Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: A comprehensive review. Clin Rev Allergy Immunol 2015;49:177-191. https://doi.org/10.1007/s12016-014-8416-0.

Turgay-Yagmur I, Guzelkucuk Z, Yarali N, Ozyoruk D, Toyran M, Civelek E, et al. Evaluation of hypersensitivity reactions to cancer chemotherapeutic agents in pediatric patients. Ann Allergy Asthma Immunol 2020;124:350-356. https://doi.org/10.1016/j.anai.2020.01.010.

Henry A, Charpiat B, Perol M, Vial T, de Saint Hilaire PJ, Descotes J. Paclitaxel hypersensitivity reactions: assessment of the utility of a test-dose program. Cancer J 2006;12:237-245. https://doi.org/10.1097/00130404-200605000-00013.

Ratanajarusiri T, Sriuranpong V, Sitthideatphaiboon P, Poovoravan N, Vinayanuwat C, Parinyanitikul N, et al. A Difference in the incidences of hypersensitivity reactions to original and generic taxanes. Chemotherapy 2017;62:134-139. https://doi.org/10.1159/000450748.

Koshiba H, Hosokawa K, Kubo A, Miyagi Y, Oda T, Miyagi Y, et al. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer 2009;19:460-465. https://doi.org/10.1111/IGC.0b013e3181a1bf2e.

Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol 2014;15:1. https://doi.org/10.1186/2050-6511-15-1.

Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 2009;76:36-41. https://doi.org/10.1159/000178163.

Sohn KH, Kang DY, Kim JY, Lee SY, Lee KH, Han SW, et al. Incidence and risk of oxaliplatin-induced hypersensitivity in patients with asymptomatic prior exposure: A prospective observational study. J Allergy Clin Immunol Pract 2018;6:1642-1648.e1642. https://doi.org/10.1016/j.jaip.2017.12.026.

Tham EH, Cheng YK, Tay MH, Alcasabas AP, Shek LP. Evaluation and management of hypersensitivity reactions to chemotherapy agents. Postgrad Med J 2015;91:145-150. https://doi.org/10.1136/postgradmedj-2014-132686.

Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. Allergy 2014;69:420-437. https://doi.org/10.1111/all.12350.

Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 2013;1:494-500. https://doi.org/10.1016/j.jaip.2013.06.002.

Kolomeyevskaya NV, Lele SB, Miller A, Riebandt GC, Blum BL, Odunsi KO, et al. Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin. Int J Gynecol Cancer 2015;25:42-48. https://doi.org/10.1097/igc.0000000000000307.

Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994;53:121-122. https://doi.org/10.1006/gyno.1994.1098.

Rose PG, Metz C, Link N. Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization. Int J Gynecol Cancer 2014;24:1603-1606. https://doi.org/10.1097/igc.0000000000000295.

Dizon DS, Schwartz J, Rojan A, Miller J, Pires L, Disilvestro P, et al. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol 2006;100:149-151. https://doi.org/10.1016/j.ygyno.2005.08.004.

Sánchez-Muñoz A, Jiménez B, García-Tapiador A, Romero-García G, Medina L, Navarro V, et al. Cross-sensitivity between taxanes in patients with breast cancer. Clin Transl Oncol 2011;13:904-906. https://doi.org/10.1007/s12094-011-0753-3.

Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol 2016;137:1154-1164.e1112. https://doi.org/10.1016/j.jaci.2015.10.039.

Pellegrino B, Boggiani D, Tommasi C, Palli D, Musolino A. Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review. Acta Biomed 2017;88:329-333. https://doi.org/10.23750/abm.v88i3.6138.

Picard M. Management of hypersensitivity reactions to taxanes. Immunol Allergy Clin North Am 2017;37:679-693. https://doi.org/10.1016/j.iac.2017.07.004.

Otani IM, Wong J, Banerji A. Platinum chemotherapy hypersensitivity: Prevalence and management. Immunol Allergy Clin North Am 2017;37:663-677. https://doi.org/10.1016/j.iac.2017.06.003.

Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:4611-4614. https://doi.org/10.1200/jco.2003.05.539.

Pagani M, Bavbek S, Dursun AB, Bonadonna P, Caralli M, Cernadas J, et al. Role of skin tests in the diagnosis of immediate hypersensitivity reactions to taxanes: Results of a multicenter study. J Allergy Clin Immunol Pract 2019;7:990-997. https://doi.org/10.1016/j.jaip.2018.09.018.

Giavina-Bianchi P, Galvão VR, Picard M, Caiado J, Castells MC. Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy. J Allergy Clin Immunol Pract 2017;5:728-736. https://doi.org/10.1016/j.jaip.2016.11.006.

Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010;65:1357-1366. https://doi.org/10.1111/j.1398-9995.2010.02441.x.

Kendirlinan R, Gümüşburun R, Çerçi P, Özbek E, Altıner S, Çelebi Sözener Z, et al. Rapid drug desensitization with chemotherapeutics (platins, taxanes, and others): A single-center retrospective study. Int Arch Allergy Immunol 2019;179:114-122. https://doi.org/10.1159/000496745.

Caimmi S, Caffarelli C, Saretta F, Liotti L, Crisafulli G, Cardinale F, et al. Drug desensitization in allergic children. Acta Biomed 2019;90:20-29. https://doi.org/10.23750/abm.v90i3-S.8158.

Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-580. https://doi.org/10.1016/j.jaci.2008.02.044.

Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract 2016;4:497-504. https://doi.org/10.1016/j.jaip.2015.12.019.

Karaatmaca B, Aytac S, Sahiner UM, Sekerel BE, Soyer O. Successful oral desensitization with dasatinib in delayed cutaneous hypersensitivity reactions. Ann Allergy Asthma Immunol 2019;123:216-217. https://doi.org/10.1016/j.anai.2019.05.011.

Bavbek S, Lee MJ. Subcutaneous injectable drugs hypersensitivity and desensitization: Insulin and monoclonal antibodies. Immunol Allergy Clin North Am 2017;37:761-771. https://doi.org/10.1016/j.iac.2017.06.001.

Demir S, Soyer O, Bilginer Y, Sag E, Sahiner UM, Buyuktiryaki B, et al. Desensitisation overcomes rituximab- and tocilizumab-related immediate hypersensitivity in childhood. Clin Exp Rheumatol 2020;38:552-557.

Lopez-Gonzalez P, Madrigal-Burgaleta R, Carpio-Escalona LV, Bernal-Rubio L, Guerra E, Berges-Gimeno MP, et al. Assessment of antihistamines and corticosteroids as premedication in rapid drug desensitization to paclitaxel: Outcomes in 155 procedures. J Allergy Clin Immunol Pract 2018;6:1356-1362. https://doi.org/10.1016/j.jaip.2017.11.013.

Fouda GE, Bavbek S. Rituximab hypersensitivity: From clinical presentation to management. Front Pharmacol 2020;11:572863. https://doi.org/10.3389/fphar.2020.572863.

Cómo citar
1.
Martínez-Castillo DM, Ardila-Herrera JC, Calle-Álvarez AM, Chinchilla-Mejía CF. Reacciones de hipersensibilidad a quimioterapéuticos y biológicos. Med. Lab. [Internet]. 11 de enero de 2022 [citado 22 de enero de 2022];26(1):63-0. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/560
Publicado
2022-01-11
Sección
Artículos de revisión
Crossref Cited-by logo